NCT07198191Active, not recruiting
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Population Cohort Study
Source: ClinicalTrials.gov · Last updated 30 Sept 2025
Brief summary (registry, in English)
This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). Using the nationwide database from the Korean National Health Insurance Service, the investigators will compare cardiovascular outcomes between patients treated with SGLT2 inhibitors and those treated with dipeptidyl peptidase-4 (DPP4) inhibitors after AMI. The study period includes patients diagnosed with AMI between September 2014 and June 2021, with follow-up data available through June 2022. The primary outcomes include major cardiovascular events (death, myocardial infarction, stroke) and bleeding events. This study will provide real-world evidence on the effectiveness and safety of SGLT2 inhibitors in routine clinical practice following AMI among patients with T2DM in Korea.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 200000 (estimated)
- First submitted
- 26 Aug 2025
- Start date
- Sept 2014
- Primary completion date
- Jun 2022
- Lead sponsor
- Yonsei University
- Diseases
- Heart failure, Type 2 diabetes
- NCT number
- NCT07198191
What you commit to
- Study type: Observational
- Planned participants: 200000
- From Sept 2014 to the primary completion date, Jun 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No use of either SGLT2 inhibitor or DPP4 inhibitor after index AMI
- Short-term use of SGLT2 inhibitor or DPP4 inhibitor (less than 30 days)
- Concomitant use of SGLT2 inhibitor and DPP4 inhibitor
Other illness
- Diagnosis of type 1 diabetes mellitus
- Gestational diabetes mellitus
- End-stage renal disease (ESRD) or history of kidney transplantation
Other
- Incomplete or missing data for key study variables
Who the study is looking for
- Adults aged ≥19 years
- Hospitalization with a primary diagnosis of acute myocardial infarction between September 2014 and June 2021
- Diagnosis of type 2 diabetes mellitus (T2DM)
- Prescription of either an SGLT2 inhibitor or a DPP4 inhibitor after index AMI
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yongin Severance Hospital, Yonsei University Health System Coordinator of this site? Confirm its status | Yongin | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.